Identification of a Novel Substance P–Neurokinin-1 Receptor MicroRNA-221-5p Inflammatory Network in Human Colonic Epithelial Cells  by Fang, Kai et al.
ORIGINAL RESEARCHIdentiﬁcation of a Novel Substance P–Neurokinin-1 Receptor
MicroRNA-221-5p Inﬂammatory Network in Human Colonic
Epithelial Cells
Kai Fang,1 Aristea Sideri,1 Ivy Ka Man Law,1 Kyriaki Bakirtzi,1 Christos Polytarchou,2
Dimitrios Iliopoulos,2 and Charalabos Pothoulakis1
1Inﬂammatory Bowel Disease Center and 2Center for Systems Biomedicine, Division of Digestive Diseases, David Geffen
School of Medicine, University of California, Los Angeles, CaliforniaAbbreviations used in this paper: as, anti-sense; CAPE, caffeic acid
phenethyl ester; COL2a1, collagen, type II, a 1; CXCL10, C-X-C motif
chemokine 10; DSS, dextran sulfate sodium; IBD, inﬂammatory bowel
disease; IL, interleukin; IL-6R, interleukin-6 receptor; JAK-STAT, Janus
kinase/signal transducer and activator of transcription; JNK, c-Jun N-
terminal kinase; miRNA, microRNA; NF-kB, nuclear factor-kB; NK-1R,
neurokinin-1 receptor; RT-PCR, real-time polymerase chain reaction;
siRNA, small-interfering RNA; SP, substance P; TNBS, trinitrobenzene
sulfonic acid; TNFa, tumor necrosis factor-a; UC, ulcerative colitis;
UTR, untranslated region.
Most current article
© 2015 The Authors. Published by Elsevier Inc. on behalf of the AGA
Institute. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2352-345X
http://dx.doi.org/10.1016/j.jcmgh.2015.06.008SUMMARY
Substance P–neurokinin-1 (NK-1R) microRNA-221-5p (miR-
221-5p) network regulates inﬂammation in human colonic
epithelial cells through inhibition of interleukin-6R expres-
sion. Because silencing of miR-221-5p exacerbates experi-
mental colitis, the use of miR-221-5p mimics may be a
promising approach for colitis treatment.
BACKGROUND & AIMS: Substance P (SP), a neuropeptide
member of the tachykinin family, plays a critical role in colitis.
MicroRNAs (miRNAs) are small noncoding RNAs that negatively
regulate gene expression. We examined whether SP modulates
expression of microRNAs in human colonic epithelial cells.
METHODS: We performed microRNA proﬁling analysis of SP-
stimulated human colonic epithelial NCM460 cells over-
expressing neurokinin-1 receptor (NCM460-NK-1R). Targets of
SP-regulated microRNAs were validated by real-time poly-
merase chain reaction (RT-PCR). Functions of miRNAs were
tested in NCM460-NK-1R cells and the trinitrobenzene sulfonic
acid (TNBS) and dextran sulfate sodium (DSS) models of colitis.
RESULTS: SP stimulated differential expression of 29 micro-
RNAs, including miR-221-5p, the highest up-regulated miR
(by 12.6-fold) upon SP stimulation. Bioinformatic and luciferase
reporter analyses identiﬁed interleukin-6 receptor (IL-6R)
mRNA as a direct target of miR-221-5p in NCM460 cells.
Accordingly, SP exposure of NCM460-NK-1R cells increased
IL-6R mRNA expression, and overexpression of miR-221-5p
reduced IL-6R expression. Nuclear factor kB and c-Jun N-ter-
minal kinase inhibition decreased SP-induced miR-221-5p
expression. MiR-221-5p expression was increased in both
TNBS- and DSS-induced colitis and in colonic biopsy samples
from ulcerative colitis but not Crohn’s disease patients
compared with controls. In mice, intracolonic administration
of a miR-221-5p chemical inhibitor exacerbated TNBS- and
DSS-induced colitis and increased colonic tumor necrosis fac-
tor-a, C-X-C motif chemokine 10 (Cxcl10), and collagen, type II,
a 1 (Col2a1) mRNA expression. In situ hybridization in TNBS-
and DSS-exposed colons revealed increased miR-221-5p
expression primarily in colonocytes.
CONCLUSIONS: Our results reveal a novel NK-1R-miR-221-5p-
IL-6R network that protects from colitis. The use of miR-221-5p
mimics may be a promising approach for colitis treatment. (CellMol Gastroenterol Hepatol 2015;1:503–515; http://dx.doi.org/
10.1016/j.jcmgh.2015.06.008)
Keywords: Colitis; Inﬂammation; MicroRNA; Substance P.ubstance P (SP), an 11-amino-acid peptide memberSof the tachykinin family, is expressed in many organs
including the intestine.1 SP plays a critical role in colitis
pathophysiology by interacting with its high-afﬁnity neu-
rokinin-1 receptor (NK-1R)2–4 and activating signaling
pathways related to nuclear factor-kB (NF-kB)5–7 and c-Jun
N-terminal kinase (JNK)8 in different cell types, including
colonocytes.5,8,9 NK-1R expression is increased in the colon
of inﬂammatory bowel disease (IBD) patients,10,11 further
suggesting an important role in IBD pathogenesis.
MicroRNAs (miRNA, MiR) represent a class of small non-
coding single-stranded RNAs that control translation and
mRNA degradation by binding to target mRNAs through
complementary sequences.12 Functional studies have
demonstrated that miRNAs play critical roles in many phys-
iologic and pathologic conditions, including inﬂammation13
and colitis pathogenesis.14–16 There is limited evidence,
however, on the interaction between the SP/NK-1R system
and miRNAs. Both miR-130a and miR-206 were found to
regulate SP synthesis and release in neuronal cells,17 and
miR-449b and miR-500 modulate NK-1R expression in
human astrocytoma cells.18 Moreover, a miR-203 mimic
blocked SP-mediated increased phospholipase-A2 activating
protein expression in keratinocytes.19 However, whether SP
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response is related to the ability of SP to regulate colitis is not
known. We performed amiRNA expression analysis to detect
the miRNA signature upon SP stimulation of human colonic
NCM460 epithelial cells.
Materials and Methods
Cell Studies and Reagents
NCM460 human colonic epithelial cells overexpressing
NK-1R (NCM460-NK-1R), cultured as previously described
elsewhere,5 were starved in serum-free medium overnight
and then stimulated with 0.1 mM SP at speciﬁc times. CAPE
(caffeic acid phenethyl ester; cat. no. C8221), a speciﬁc in-
hibitor of NF-kB, was obtained from Sigma-Aldrich (St.
Louis, MO), and the JNK inhibitor SP600125 (cat no. 8177)
was obtained from Cell Signaling Technology (Beverly, MA).
SP was purchased from Sigma-Aldrich (cat. no. S6883).
Rabbit anti-interleukin-6 receptor (anti-IL6R; SC-661) was
purchased from Santa Cruz Biotechnology (Dallas, TX).
Mouse anti-b-actin was obtained from Sigma-Aldrich.
Transfection Experiments
Inhibitors of miR-221-5p (cat. no. 4464084), negative
anti-miRNAs controls (cat. no. 4464076), a miR-221-5p
mimic (cat. no. 4464067), and mimic miRNA controls (cat.
no. 4464058) were purchased from Life Technologies
(Carlsbad, CA). Mouse anti-miR-221-5p and negative control
were purchased from Exiqon (Vedbæk, Denmark); the target
sequence of anti-miR-221-5p is TGTAACATACGGTCC, and
the target sequence of anti-miR-control is ACGTCTAT
ACGCCCA. Lipid-based siPORTNeoFX Transfection Agent was
purchased from Ambion (AM4511; Ambion/Life Technolo-
gies, Austin, TX), Lipofectamine 2000 was purchased from
Life Technologies (cat. no. 52758). NF-kB p65 small-
interfering RNA (siRNA; sc-29140), c-Jun siRNA (sc-29223),
and control siRNA (sc-37007) were purchased from Santa
Cruz Biotechnology.
NCM460-NK-1R cells were transfected with siRNA using
Lipofectamine RNAiMAX (Life Technologies). For miR-221-5p
silencing or overexpression, the cells were transfected with
antisense-miR-221-5p (as-miR-221-5p) ormiR-221-5pmimic,
respectively. Cells transfected with siRNA-control, antisense-
control miR, or miR-mimic control served as controls.
Microarray Analysis of miRNA Expression
The miRNA microarray experiments were performed
using the TaqMan low-density array human miRNA v1.0
system, which contains 365 microRNAs. The high-capacity
reverse transcription reagent for cDNA was from Applied
Biosystems (cat. no. 4368813; Foster City, CA). The real-time
polymerase chain reaction (RT-PCR) primers were pur-
chased from Life Technologies, except the miR-221-5p
primers which were from Exiqon (cat. no. 204302). The to-
tal RNA of the NCM460-NK-1R cells were isolated by using
TRIzol reagents, and the RNA concentration were deter-
mined by Nanodrop. Data were collected and normalized to
nonfunctional small RNA internal controls. The results were
validated using quantitative reverse-transcription PCR. ThemiRNA template for RT-PCR analysis was prepared using
Exiqon reagents. RNU1A1 (cat. no. 203909; Exiqon) ex-
pression was used as the internal control. The threshold
cycle (Ct) value formula was used to calculate the relative
expression of selected miRNAs, as we previously reported
elsewhere.20
Human Inﬂammatory Bowel Disease
Biopsy Specimens
Total RNAs from the colon tissues of patients with active
ulcerative colitis (UC) (n ¼ 14), active Crohn’s disease
(n ¼ 15), and healthy individuals (n ¼ 9–10) were pur-
chased from OriGene (Rockville, MD). These biopsy samples
were obtained through strict institutional review board
protocols and with full, documented patient consent,
all from accredited U.S.-based medical institutions (www.
origene.com). Conversion of the cDNA of RNA samples
was performed as described earlier, and the levels of NK-1R,
IL-6R and miR-221-5p were determined by quantitative
RT-PCR analysis.
Luciferase Assays
IL-6R 30-UTR (untranslated region) containing the two
predicted binding sites and mutated sequences were
chemically synthesized by GENEWIZ (South Plainﬁeld, NJ).
The wild-type and mutants of the IL-6R 30-UTR sequence
were then subcloned into the luciferase reporter vector
from SwitchGear Genomics (cat. no. 32011; Carlsbad, CA).
NCM460-NK-1R cells were transfected using Lipofectamine
2000 (Invitrogen, Carlsbad, CA) with luciferase reporter
constructs containing the wild-type or mutant of 30-UTR of
IL-6R and the miR-221-5p mimic. Cell lysates were pre-
pared 24 hours after transfection, and luciferase activity
was measured using the LightSwitch Luciferase Assay Kit
from SwitchGear Genomics (cat no. LS100) according to the
manufacturer’s instructions.
Immunoblot Analyses
NCM460-NK-1R cells were washed with ice-cold phos-
phate-buffered saline and incubated with radiolabeled
immunoprecipitation assay buffer containing the protease
inhibitors and sodium orthovanadate (Santa Cruz Biotech-
nology) for 5minutes on ice. Equal amount of cell lysateswere
subjected to sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred topolyvinylidene
ﬂuoride membranes. The membranes were blocked (phos-
phate-buffered saline, 5% nonfat dry milk, 0.05% Tween-20)
and probed with antibodies followed by corresponding
horseradish peroxidase-labeled secondary antibodies. Blots
were developed with an enhanced chemiluminescence re-
agent (cat. no. 34080; Thermo Fisher Scientiﬁc,Waltham,MA).
In Situ Hybridization
In situ hybridization was performed on mice colon tissue
from C57BL/6J mice after treatement with trinitrobenzene
sulfonic acid (TNBS) (7 days) or dextran sodium sulfa-
te(DSS) (6 days), as we previously reported elsewhere21
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for mouse miR-221-5p (cat no. 99999-15; Exiqon) was as
follows: 50-ACAGAAATCTACATTGTATGCCA. The experi-
ments were performed according to the manufacturer’s in-
structions using miRCURY LNA microRNA ISH optimization
Kit (FFPE; Exiqon).
Experimental Colitis
We induced colitis via TNBS and DSS treatment with
modiﬁcations of previously described protocols.21 All ani-
mal studies were approved by the institutional animal care
and use committee. Total RNA from the colonic tissues of
the TNBS model was puriﬁed by use of the miReasy Mini Kit
(Qiagen, Valencia, CA) and from the DSS model by use of the
lithium chloride precipitation method.22 Tissue sections
were scored for histopathology analyses in a double-blinded
manner, as previously reported elsewhere.21
Trinitrobenzene Sulfonic Acid-Induced Colitis. Animals
were maintained at University of California–Los Angeles
animal research facility and received standard pelleted chow
and water ad libitum. The 6- to 8-week-old male C57BL/6J
mice (n ¼ 5–8 per group) received a 50-mL intracolonic in-
jection of 40 mg/kg TNBS (Fluka, Ronkonkoma, NY) in 30%
ethanol, using a 1-mL syringe (Becton Dickinson, Laguna
Hills, CA) ﬁtted with a polyethylene cannula (Intramedic PE-
20 tubing; Becton Dickinson). The control groups were
injected with 50 mL of 30% ethanol intracolonically. The
mice were held head down for 1 minute after the enema
administration to ensure the containment of the TNBS so-
lution into the colon. The mice returned to their cages; they
were sacriﬁced after 7 days by cervical dislocation, and the
colonic tissues were collected.
To assess the effect of miR-221-5p in TNBS-induced
colitis, mice were intracolonically administered 40 mg/kg
TNBS; then, on days 1, 3 and 5, they were intracolonically
injected with 40 mg of miRCURY LNA Inhibitor probe in vivo
against mmu-miR-221-5p (Exiqon). Brieﬂy, the appropriate
amount of oligonucleotides against mmu-miR-221-5p and its
respective control were resuspended in 100 mL of Opti-MEM
with 2 mL of lipofectamine 2000 and administered intra-
colonically. On day 7 the mice were sacriﬁced, and their
colon tissue was collected for H&E staining and RNA
expression analysis.
DSS-Induced Colitis. To assess the miRNA expression,
1% DSS was dissolved in the drinking water and admin-
istered to C57BL/6J mice for 5 days (n ¼ 5–8 mice per
group). To test the effect of miR-221-5p in DSS-induced
colitis, mice were administered 1% DSS, then, on days 1,
3, and 5, the mice were intracolonically injected with 40 mg
anti-miR-221-5p or anti-miR-control, as described earlier.
On day 6 the mice were sacriﬁced, and their colon tissue
was collected for H&E staining and RNA expression
analysis.
Statistical Analysis
Student t test for two-group comparisons and analysis of
variance for multiple-group comparisons were performed
to determine any statistically signiﬁcant differencesbetween the experimental groups. P < .05 was considered
statistically signiﬁcant. All results are expressed as mean ±
standard deviation.Results
Substance P Regulates Expression of
MicroRNAs in Human Colonic Epithelial Cells
To investigate the effect of SP on miRNA expression in
human colonic epithelial cells, we used 0.1 mM SP to stim-
ulate NCM460-NK-1R cells in serum-free medium at 0.5 and
6 hours. This SP concentration was used in previous studies
to stimulate NCM460-NK-1R cells.9,23 Total RNA was iso-
lated, and the miRNA array analysis was performed as we
previously reported.24 We found that 29 miRNAs (18 up-
regulated and 11 down-regulated) had altered expression
upon SP stimulation (Figure 1A).
Hierarchical clustering analysis revealed that four
different clusters of miRNAs were affected by SP. Specif-
ically, the up-regulated miRNAs were divided into miRNAs
that showed an early and stable response (expression was
increased at 30 minutes of stimulation) and a late response
(expression was no different at 30 minutes of stimulation
but was altered after 6 hours of stimulation) (see
Figure 1B). Similarly, the down-regulated miRNAs were
divided into early (cluster 3) or late (cluster 4) response
clusters (see Figure 1C). Among the up-regulated miRNAs,
miR-221 and miR-222 showed the highest increase.
MiR-221 and miR-222 are encoded in a cluster on the X
chromosome. Pre-miR-221 is processed in the cytoplasm
and produces two forms of mature miRNA: miR-221-5p
(also named as miR-221*) and miR-221-3p (normally
referred as miR-221). RT-PCR analysis validated that miR-
221-5p, miR-221-3p, miR-222-5p, and miR-222-3p were
substantially increased by SP at 30 minutes, with a sus-
tained increase over controls at 6, 12, and 24 hours
(Figure 2). Among those four mature miRNAs, miR-221-5p
showed a more substantial increase compared with other
three mature miRNAs. Thus, we next focused on SP-miR-
221-5p interactions.MicroRNA-221-5p and Neurokinin-1 Receptor
Are Up-Regulated in Human Ulcerative
Colitis Tissues
Our results indicated that NK-1R signaling is linked to
increased miR-221-5p expression in human colonic epithe-
lial cells. Previous results had demonstrated increased NK-
1R expression in the colon of IBD patients.10,25 Therefore,
we next examined whether miR-221-5p expression is also
increased in human IBD samples. Our results showed
increased expression of miR-221-5p in UC biopsy samples
(n ¼ 14) compared with biopsy samples from controls
(n ¼ 10, P ¼ .01; Figure 3A). However, we found no statis-
tically signiﬁcant differential expression of miR-221-3p, miR-
222-5p, or miR-221-3p in those samples. The expression of
miR-221-5p was not statistically signiﬁcantly different in the
Crohn’s disease tissues (n ¼ 15) compared with the control
samples (n ¼ 9, P ¼ .28). Examination of the same UC
Figure 1. Substance P
(SP)-regulated micro-
RNAs (miRNA) in colon
epithelial cells. (A) Heat
map represents differen-
tially expressed miRNAs
after 0.1 mM SP treatment
(0.5 and 6 hours) in
NCM460-NK-1R cells. Red
indicates up-regulated
miRNAs, and green in-
dicates down-regulated
miRNAs. Cluster of (B)
SP-induced and (C) SP-
suppressed miRNAs ac-
cording to their response
dynamics.
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when compared with controls (see Figure 3A).Substance P Regulates MicroRNA-221-5p
Expression Through Nuclear Factor-kB and
c-Jun N-Terminal Kinase Pathways
Because NK-1R coupling activates the transcription fac-
tor NF-kB and JNK5–8 and these pathways are involved in
experimental colitis,26,27 we examined their involvement in
SP-regulated miR-221-5p expression. Bioinformatics anal-
ysis by using the online transcription factor search softwareTFSearch (Computational Biology Research Consortium,
Tokyo, Japan) indicated the presence of NF-kB binding sites
(The sequence is 50-GGAACGTCCC-30, from 45750897bp to
45750906 bp of X chromosome, localized in 4740 bp up-
stream of miR-221, conﬁrming a recent report.28)
To examine the functional role of NF-kB on miR-221
expression levels, we used the NF-kB inhibitor CAPE,
which prevents translocation of the p65 subunit of NF-kB to
the nucleus.29 NCM460-NK-1R cells were treated with 10
mM CAPE for 30 minutes before SP (0.1 mM) stimulation for
6 hours. Our results showed that CAPE signiﬁcantly reduced
miR-221-5p expression (Figure 4A). Moreover, silencing of
Figure 2. Quantitative
real-time polymerase
chain reaction (RT-PCR)
detection of substance P
(SP) induced mature
microRNA (miRNA) ex-
pression. Mature miRNAs
expression quantiﬁcation
was performed after 0.1
mM SP treatment (0.5, 6,
12, and 24 hours) of
NCM460-NK-1R cells.
Expression levels of miR-
221-5p, miR-221-3p, miR-
222-5p, and miR-222-3p
were assessed by RT-
PCR analysis. *P < .05,
data show mean ± stan-
dard deviation of triplicate
samples per experimental
condition.
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decreased SP-induced miR-221-5p expression in NCM460-
NK-1R cells compared with control siRNA (see Figure 4B).
Previous results indicated that c-Jun regulates miR-221
expression in lung, liver, and prostate cancer cells.28,30 To
address the involvement of c-Jun in SP-increased miR-221-
5p expression, we pretreated NCM460-NK-1R cells with
50 mM of the JNK inhibitor SP60012531 and found that SP-
stimulated miR-221-5p expression was almost normalized
by SP600125 (see Figure 4C). To conﬁrm this result, we
silenced c-Jun using a siRNA approach as described in
Materials and Methods. As shown in Figure 4D, c-Jun
silencing reduced SP-induced increased miR-221-5p
expression. Taken together, these results indicate that SP
regulates miR-221-5p expression in human colonic epithe-
lial cells through activation of NF-kB and JNK.MicroRNA-221-5p Regulates Directly Interleukin-6
Receptor Expression in Human Colonic
Epithelial Cells
MicroRNAs negatively regulate gene expression by bind-
ing to complementary sequences in the 30 untranslated region
(30-UTR) of their target genes. Because SP regulates expres-
sion of several proinﬂammatory genes, we next determined
whethermiR-221-5p regulates directly inﬂammation-related
genes using bioinformatics.Our bioinformatics analysis, using a miRNA target pre-
diction program from DIANA laboratory,32 showed the
presence of two binding sites for miR-221-5p in the 30-UTR
of human IL-6R mRNA sequence (NM_00565.3) (Figure 5A).
A luciferase activity assay using plasmids containing the
miR-221-5p binding sites in the 30-UTR of IL-6R indicated
that cells transfected with a miR-221-5p mimic had lower
luciferase activity compared with control-miR-mimic-
treated NCM460-NK-1R cells (n ¼ 3, P < .05; see
Figure 5C), suggesting that IL-6R 30-UTR is sufﬁcient to
confer miR-221-5p regulation (see Figure 5B and C).
Importantly, when both the miR-221-5p seed regions in the
IL-6R 30-UTR were mutated, miR-221-5p regulation was
abolished (see Figure 5B and C).
To elucidate the effects of miR-221-5p on IL-6R mRNA
expression levels, we transfected NCM460-NK-1R cells with
0.1 mM of antisense miR-221-5p (as-miR-221-5p), or miR-
221-5p mimic, or their controls using siPORT NeoFX (Life
Technologies). After 48 hours, the cells were placed in
serum-free medium overnight, and then they were stimu-
lated with 0.1 mM SP. The total RNA was isolated for RT-PCR
analysis. As shown in Figure 5D, miR-221-5p silencing
increased the IL-6R levels. Conversely, miR-221-5p mimic
treatment reduced the IL-6R levels compared with the mimic
control-treated cells (see Figure 5E). Thus, miR-221-5p in-
hibits IL-6R mRNA expression in human colonic epithelial
cells. Moreover, treatment of cells with miR-221-5p mimic
Figure 3. Level of miR-
221-5p in inﬂammatory
bowel disease tissues. (A)
Expression of microRNA
(miR)-221-5p, neurokinin-1
receptor (NK-1R), and
interleukin-6 receptor (IL-
6R) in human ulcerative
colitis (UC) tissue samples
(n ¼ 14) compared with
control tissue samples (n ¼
10). *P < .05, data show
mean ± standard devia-
tion. (B) Correlation of miR-
221-5p levels with NK-1R
and IL-6R. The correlation
coefﬁcient was calculated
using Prism6 (GraphPad
Software, San Diego, CA).
(C) Schematic representa-
tion of proposed sub-
stance P (SP)–miRNA
signaling pathway in hu-
man colonic epithelial
cells. After binding with the
NK-1R receptor, SP stim-
ulates miR-221-5p expres-
sion via nuclear factor-kB
(NF-kB) and c-Jun N-ter-
minal kinase (JNK) activa-
tion in human colonic
epithelial cells. MiR-221-5p
regulates inﬂammation
through down-regulation
of IL-6R expression.
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results indicate that IL-6R is a downstream target of miR-
221-5p in human colonocytes.
Based on the negative correlation of miR-221-5p to
IL-6R expression shown here, we examined IL-6R mRNA
levels in the same colon samples. As shown in Figure 3A,
the IL-6R expression levels were statistically signiﬁcantly
decreased (by 23%, P < .05) compared with controls.
NK-1R levels were correlated positively with miR-221-5p
(R2 ¼ 0.8476), whereas miR-221-5p levels correlated
negatively with IL-6R (R2 ¼ 0.5876) (see Figure 3B).
These results indicate that NK-1R-miR-221-5p signaling is
activated and IL-6R expression is decreased in the colon
during active UC.MicroRNA-221-5p Is Up-Regulated in
Experimental Colitis
To begin to address a possible functional role for miR-
221-5p in the pathophysiology of colitis, we ﬁrst examined
colonic expression of miR-221-5p in two chemical models of
experimental colitis. As shown in Figure 6A, colonic
expression of miR-221-5p was signiﬁcantly up-regulated
3 and 7 days after intracolonic administration of TNBS.Moreover, expression of miR-221-5p was also increased by
twofold 5 days after administration of 1% DSS into the
drinking water of C57BL/6J mice (see Figure 6C).
To examine the cellular localization of miR-221-5p, we
performed in situ hybridization using a miR-221-5p probe
in colon tissue sections obtained from control and TNBS- or
DSS-treated mice as described inMaterials and Methods. Our
results showed that miR-221-5p expression is increased in
the colonic mucosa, primarily in colonic epithelial cells in
TNBS- or DSS-exposed mice, compared with controls (see
Figure 6B and D).Intracolonic Silencing of MicroRNA-221-5p
Enhances Trinitrobenzene Sulfonic Acid–Induced
Colitis
We next tested the importance of miR-221-5p in colitis
pathogenesis in the TNBS colitis model. Mice were intra-
colonically administered 40 mg/kg of TNBS on day 0, then
on days 1, 3, and 5 they were intracolonically administered
anti-sense (as) miR-221-5p or as-miRNA-control (40 mg/
mouse). On day 7 the colon tissues were collected for
further analysis (see the experimental design diagram in
Figure 7A).
Figure 4. Substance P
(SP) regulates microRNA
(miR)-221-5p expression
through nuclear factor-
kB (NF-kB) and c-Jun N-
terminal kinase (JNK)
pathways. MiR-221-5p
expression was assessed
by real-time polymerase
chain reaction (RT-PCR).
(A) NCM460-NK-1R (neu-
rokinin-1 receptor) cells
were pretreated with the
NF-kB inhibitor caffeic acid
phenethyl ester (CAPE, 10
mM) 30 minutes before SP
exposure for 6 hours. (B)
MiR-221-5p levels in cells
transfected with siRNA-
p65 for 48 hours before
SP exposure of 6 hours. (C)
NCM460-NK-1R cells were
pretreated with the JNK
inhibitor SP600125 30 mi-
nutes before SP exposure
for 6 hours. (D) MiR-221-5p
levels in cells transfected
with siRNA-c-Jun for 48
hours before SP exposure
for 6 hours. *P < .05, data
show mean ± standard
deviation of triplicate.
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5p, we measured colonic miR-221-5p expression in the
different mouse groups and found reduced endogenous miR-
221-5p levels (by 80%) in as-miR-221-5p-exposed mice
compared with those exposed to as-control miR (see
Figure 7D). Mice treated with TNBS showed epithelial
destruction and inﬂammation and an increased histopa-
thology score compared with mice who received an intra-
colonic administration of vehicle (see Figure 7C). We found
no difference in the histopathology score and levels of miR-
221-5p expression in the mice treated with TNBS alone, or
TNBS with control as-miR, or TNBS with Lipofectamine
vehicle (see Figure 7C and D). However, the TNBS-exposed
mice treated with as-miR-221-5p demonstrated more con-
voluted crypts and epithelial cell damage than the as-miRNA
control-treated mice (see Figure 7B). These changes are also
depicted in the increased histopathology score in TNBS-
exposedmice after as-miR-221-5p treatment (see Figure 7C).
We also found a marked increase in the levels of tumor
necrosis factor-a (TNFa) expression after silencing miR-221-
5p expression in TNBS-exposed mice. The expression of the
neutrophil chemoattractant C-X-C motif chemokine 10
(Cxcl10) was also signiﬁcantly increased (see Figure 7E). Our
results also demonstrate increased expression of collagen,
type II, a1 (Col2a1) mRNA (see Figure 7E), an importantmolecule involved in tissue remodeling andﬁbrosis,33,34 anda
trend for increased expression of CXCL1 mRNA (by twofold),
although it was not statistically signiﬁcant (n ¼ 8 per group,
P > .05). We did not ﬁnd any signiﬁcant further increase in
myeloperoxidase mRNA expression after si-miR-221-5p
treatment (data not shown). Moreover, there was no in-
crease in colonic IL-6R levels in TNBS-exposed as-miR-221-
5p-treatedmice (data not shown). These results indicated that
miR-221-5p regulates experimental colitis by modulating
expression of proinﬂammatory and ﬁbrosis-related genes.Anti-MicroRNA-221-5p Exacerbates Dextran
Sulfate Sodium–Induced Colitis
Currently, there is no animal colitis model that can
simulate every aspect of human IBD, and each model has its
own limits.35 To further conﬁrm the anti-inﬂammatory ef-
fect of miR-221-5p in colitis, we also used the DSS colitis
model. Mice were provided with 1% DSS in their drinking
water on day 0. Next, as-miR-221-5p or control as-miR was
injected intracolonically on days 1, 3, and 5; the mice were
sacriﬁced on day 6, and their colons were harvested for
further analysis.
Treatment with anti-miR-221-5p worsened the histologic
damage and colitis (Figure 8B), the histopathology score
Figure 5. MicroRNA
(MiR)-221-5p regulates
interleukin-6 receptor
(IL-6R) expression. (A)
Human IL-6R mRNA con-
tains two predicted miR-
221-5p binding sites. (B) A
diagram of IL-6R 30–un-
translated region reporters.
(C) Wild-type or mutant
IL-6R 30-UTR luciferase
constructs were cotrans-
fected with miR-221-5p
mimic or control mimic in
NCM460-NK-1R cells.
Luciferase activity was
determined 24 hours after
transfection, and normal-
ized luciferase activity is
shown. *P < .05, data
show mean ± standard
deviation of triplicate. (D).
MiR-221-5p down-regula-
tion increased IL-6R mRNA
expression in response
to substance P (SP) stim-
ulation. *P < .05, data
show mean ± standard
deviation of triplicate (E).
Up-regulation of miR-221-
5p decrease IL-6R mRNA
expression in response to
SP stimulation. *P < .05,
data show mean ± stan-
dard deviation of triplicate.
(F) IL-6R and b-actin pro-
tein levels are assessed by
Western blot in miR-221-
5p mimic or control-mimic
treated NCM460-NK-1R
cells.
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neutrophil inﬁltrates (see Figure 8E) compared with the
colon of DSS-exposed animals exposed to control as-miR.
Consistent with results from the TNBS colitis model, anti-
miR-221-5p treatment greatly reduced miR-221-5p expres-
sion in the colon tissue (see Figure 8C) and increased the
expression of TNFa, Cxcl10, and Col2 a 1 (see Figure 8F), and
CXCL1 mRNA (n¼ 8, P> .05) in the DSS model of colitis with
si-miR-221-5p treatment. These data further conﬁrm an anti-
inﬂammatory role for miR-221-5p in vivo.Discussion
MiRNAexpression is deregulated across a broad spectrum
of inﬂammatory disorders,13 including IBD.15,16 Levels of SP
are elevated in IBD tissues.1 SP and its high-afﬁnity receptorNK-1R have been also implicated in the pathophysiology of
both acute and chronic colitis because they regulate several
genes involved in the promotion of colitis as well mucosal
healing after colitis.1,36,37 However, the contribution of miRs
and miR-regulated pathways involved in the intestinal in-
ﬂammatory mechanisms of SP has not been studied. Our re-
sults indicate that coupling of SP to NK-1R in human colonic
epithelial cells regulates differential expression of 29miRNAs
(see Figure 1), and among them miR-21 has been implicated
in the pathogenesis of colitis and IBD.38–40 We also show that
miR-221 and miR-222 represent the highest up-regulated
miRs in response to SP (see Figure 1A and B) and that miR-
221-5p affects the pathophysiology of colitis through stimu-
lation of an anti-inﬂammatory feedback network (see
Figure 3C). Most importantly, our results indicate that this
SP-NK-1R-dependent miR-221-5p-IL-6R circuit is activated
Figure 6. MiR-221-5p expression is increased in experimental colitis. Expression levels of miR-221-5p are assessed by
real-time polymerase chain reaction (RT-PCR). (A) MiR-221-5p is increased in the colonic mucosa of trinitrobenzene sulfonic
acid (TNBS)-exposed mice. *P < .05 versus control (n ¼ 8). (B) Representative images of in situ hybridization of miR-221-5p of
colon tissues from TNBS-treated C57BL6/J mice and their control counterparts. (C) MiR-221-5p is increased in the colonic
mucosa of dextran sulfate sodium (DSS)-treated mice. *P < .05 versus control (n ¼ 7) and DSS-treated mice (n ¼ 5). (D)
Representative images of in situ hybridization of miR-221-5p of colon tissues from DSS-treated C57BL6/J mice and their
control counterparts. Scale bar: 100 mm.
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Figure 3), suggesting an important role for NK-1R-dependent
miRNA regulation in colitis.
We demonstrate that silencing of endogenous colonic
miR-221-5p enhances experimental colitis in two different
mouse chemical models. Mucosal histologic damage wors-
ened, and colonic mRNA levels of TNFa, Cxcl10, and Col2a1
were increased after intracolonic silencing of miR-221-5p in
both TNBS- and DSS-induced colitis (see Figures 7 and 8).
Interestingly, TNFa, CXCL10, and Col2a1 have been associ-
ated with the pathophysiology of IBD. Neutralization of
TNFa with monoclonal antibodies represents one of the
most promising recent therapies in IBD.41 CXCL10 is
increased in inﬂamed colons of IBD patients and stimulates
monocyte, natural killer, and T-cell migration42,43 whereas
Col2a1 is important in tissue remodeling and ﬁbrosis.33,34
We also present direct molecular and biochemical evi-
dence that IL-6R is a novel downstream target of miR-221-
5p that may mediate intestinal anti-inﬂammatory signalingafter SP-miR-221-5p interactions in human colonocytes. IL-
6R is implicated in cytokine-cytokine receptor signaling that
involves the Janus kinase/signal transducer and activator of
transcription (JAK-STAT) signaling pathways, known to be
dysregulated in T-cell-mediated, and DSS- and TNBS-
induced colitis.20,44,45 Additionally, the JAK-STAT pathway
is involved in the pathogenesis of UC,46 whereas treatment
with antibodies against IL-6R attenuates immune-mediated
and chemically induced colitis.47
The ability of SP to activate IL-6R expression and the
identiﬁcation of IL-6R as a downstream target of miR-221-5p
in human epithelial cells has not previously recognized.
Interestingly, our results indicate that SP induces IL-6R
expression and that exposure of NCM460-NK-1R cells to a
miR-221-5p mimic inhibits IL-6R expression (see Figure 5E
and F). This contradictory response is likely due to multiple
signaling pathways regulated by SP-NK-1R interactions.1
Thus, SP–NK-1R signaling may regulate IL-6R expression
not only through miR-221-5p but also via other transcription
Figure 7. Anti-sense
microRNA (as-miR)-221-
5p exacerbates trinitro-
benzene sulfonic acid
(TNBS)-induced colitis.
(A) Timeline of as-miR-
221-5p treatment in
TNBS-induced colitis. (B)
TNBS-induced histologic
changes in colons of con-
trol or as-miR-221-5p-
treated C57BL6/J mice.
Scale bar: 100 mm. (C)
Histopathology score of
as-miR-221-5p treated
mice with TNBS-induced
colitis. (D) Expression level
of miR-221-5p was as-
sessed by real-time poly-
merase chain reaction
(PCR) after intracolonic
administration of as-miR-
221-5p. *P < .05 com-
pared with controls (n ¼ 8).
(E) Expression of tumor
necrosis factor-a (TNFa),
C-X-C motif chemokine 10
(Cxcl10), and collagen,
type II, a 1 (Col2a1) in the
colon tissue of as-miR-
221-5p or as-miR-control
treated TNBS mice colitis
models. *P < .05 com-
pared with controls (n ¼ 8).
512 Fang et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 5factors activated via NK-1R signaling that can affect IL-6R
expression1 while, as shown here, miR-221-5p directly reg-
ulates IL-6R expression through binding IL-6R 30-UTR. In
addition, our bioinformatics analysis indicates that mouse IL-
6R mRNA has no binding sites for miR-221-5p, suggesting
that in the mouse other miR-221-5p downstream targets
may be involved in the effects of this miR in ameliorationof colitis suggested by our in vivo results with miR-221-5p
silencing.
A shown in Figure 4, the mechanism by which SP-NK-1R
interactions regulate expression of miR-221-5p involves
activation of NF-kB and JNK, important signaling pathways
known to be regulated by NK-1R activation.1 Our results
are in line with previous reports demonstrating that NF-kB
Figure 8. Anti-sense
microRNA (as-miR)-221-
5p regulates inﬂamma-
tion in dextran sulfate
sodium (DSS)-induced
colitis models. (A) Time-
line of as-miR-221-5p
treatment in 1% DSS-
induced colitis. (B) Histo-
logic changes in colons of
with controls or as-miR-
221-5p-treated C57BL6/J
mice in DSS colitis model.
Scale bar: 100 mm. (C)
Expression level of miR-
221-5p after intracolonic
administration of as-MiR-
221-5p. *P < .05 com-
pared with controls (n ¼ 6).
(D) Histopathology sore
of as-miR-221-5p-treated
mice with DSS-induced
colitis. (E) The poly-
morphonuclear neutrophil
inﬁltration sore of as-miR-
221-5p-treated mice with
DSS-induced colitis. (F)
Expression of TNFa, C-X-
C motif chemokine 10
(Cxcl10), and collagen,
type II, a 1 (Col2a1) in the
colon tissue of as-miR-
221-5p or anti-miR-control
treated DSS-induced coli-
tis models. *P < .05
compared with controls
(n ¼ 6).
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glioblastoma, and colorectal cancer cells.48 Importantly, our
ﬁnding demonstrates that miR-221-5p act as an anti-
inﬂammatory miRNA by controlling IL-6R expression in
human epithelial cells. IL-6R is implicated in cytokine-
cytokine receptor interactions and in the JAK-STAT
signaling pathways, known to be dysregulated in colitis
induced by T-cells,20 DSS,45 and TNBS.44
Compared with controls, IL-6R expression is decreased
in inﬂamed the colon biopsy tissues from UC patients; in the
same samples, the expression of NK-1R and miR-221-5p are
increased (see Figure 3A and B). These ﬁndings combined
with our in vitro analysis (see Figures 4 and 5) demonstrate
a positive correlation between miR-221-5p and NK-1R and
an inverse correlation with IL-6R in UC. This NK-1R-miR-
221-5p-dependent pathway, its association with the NF-kB
and JNK signaling pathways, and IL-6R as a downstreamtarget of this miR are summarized in the diagram under
Figure 3C. Previous studies, however, reported increased
soluble IL-6R in human IBD serum,49 and another study
found no differences in the relative expression of IL-6R in
blood T cells and lamina propria T cells among Crohn’s
disease, UC and control patients.47 These differences in
IL-6R expression levels comparing our study and the studies
of Atreya et al47 and Mitsuyama et al49 may be due to
different IL-6R measurement methods (ELISA, FACS, vs.
quantitative reverse-transcription PCR) and/or materials
used (serum and lamina propria T cells versus mucosal
biopsies).
Our results show increased expression of miR-221-5p
in colonic biopsies from UC patients (see Figure 3A), a dis-
ease state highly associated with colon cancer,50 and in
the colonic mucosa of mice with experimental colitis
(see Figure 6A and C). MiR-221-5p is also up-regulated in
514 Fang et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 5cancer-associated ﬁbroblasts compared with normal ﬁbro-
blast cells, in line with a role for miR-221-5p in tumori-
genesis.51 Yuan et al52 found that miR-221-5p expression
levels correlate negatively with colorectal cancer-associated
metastasis by inhibiting MBD2 expression. Interestingly,
Rokavec et al53 found that IL-6R/STAT3 pathways promote
epithelial-to-mesenchymal transition–mediated colorectal
cancer invasion and metastasis. These results,51–53 together
with our ﬁndings, suggest that miR-221-5p may regulate
colon cancer metastasis through IL-6R/STAT3-related
pathways.
In summary, we have identiﬁed miR-221-5p as a SP-
responsive miRNA that regulates IL-6R mRNA and protein
expression in human colonic epithelial cells in vitro and
regulates experimental colitis in vivo. Our studies support
that the possibility that miR-221-5p may serve as an
important anti-“inﬂamiR” by controlling IL-6R signaling
pathways under pathologic conditions. Strategies that acti-
vate miR-221-5p expression may represent a novel thera-
peutic approach for IBD treatment.References
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